Company News Summary | 12 Jul 2021

Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified

Australian Pharmaceutical Industries Provides Strategic Review and Trading Update

08:57:00 | Associate analysts

Original annuncemenet:API strategic review and trading update

Australian Pharmaceutical Industries provided an update on its recent annual strategic review and its anticipated financial results for the year ending 31 August 2021. The Company Board has decided to increase the focus of the company on its Pharmacy Distribution and two retail businesses. It confirmed that the build of its new Marsden Park distribution centre in north-west Sydney, at a cost of $50m, remains on time and within budget. It advises that the current and recent lockdowns during June and July 2021 caused the temporary closure of 72% of the non-pharmacy company-owned Priceline stores, and 75% of the Clear Skincare clinic network.

This report appeared on www.morningstar.com.au 2021 Morningstar Australasia Pty Limited

© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain appropriate financial, legal and taxation advice before making any financial investment decision. If applicable, investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/About/ FSG or phone Morningstar on 1800 03 44 55 to request a copy. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for any use or distribution of any of this information

DISCLOSURE: Employees may have an interest in the securities discussed in this report.